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828Objective: Since 1988, approximately 1100 pediatric lung transplants have been performed worldwide with
consistent improvement in survival. Similarly, survival for pediatric heart transplant has increased over the
years; however, in this cohort improvement in survival is exclusively a result of increased early (1-year) survival.
To observe if this same phenomenon exists in pediatric lung transplants, the United Network for Organ Sharing
databasewas analyzed to evaluate and characterize how pediatric lung transplant survival has changed in the past
2 decades.
Methods: The United Network for Organ Sharing database was queried for patients aged 18 years or less who
underwent lung transplantation from May 1988 to May 2008. Analysis included 959 pediatric lung transplants.
Results: Age groups were infants (1 years) (n ¼ 106 [11%]), children (2–12 years) (n ¼ 299 [31%]), and
adolescents (13 years) (n ¼ 554 [58%]). A total of 546 (57%) were girls. Kaplan–Meier survival was signif-
icantly better in the late era (2002–2008) than in all other eras (1988–1994 and 1995–2001) (P< .05). The
half-life for graft has increased significantly over the eras (early, 2.2 years; mid, 3.3 years; and late, 3.8 years).
Conditional 1-year survival (ie, mid to late survival) was not significantly different (P¼ .3) among the eras. Gen-
der, age, diagnosis, prolonged ischemic time, and cytomegalovirus mismatch did not significantly affect overall
patient or graft survival. Chronic preoperative steroid dependence (P ¼ .02), preoperative ventilatory depen-
dence (P<.001), and retransplantation (P ¼ .02) were associated with decreased survival.
Conclusions: Survival in pediatric lung transplant has increased significantly over the years, but this improve-
ment primarily reflects improvement in early survival. Survival in pediatric lung transplant after the first post-
transplant year has not changed in more than 2 decades. (J Thorac Cardiovasc Surg 2011;141:828-32)Supplemental material is available online.
The first human lung transplant was performed by Dr James
Hardy at the University of Mississippi in 1963 for an iso-
lated cancer of the lung.1 Between 1963 and 1980, approx-
imately 44 transplants were performed at medical centers
around the world with no real success. Most of these trans-
plants were performed on debilitated patients as ‘‘rescue’’
attempts after they became ventilator-dependent. Only 2 re-
cipients lived more than 1 month. The advent of new tech-
niques and immunosuppressive therapies made possible the
first successful single lung transplant, which was performede Michael E. DeBakey Department of Surgery, Division of Congenital Heart
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The Journal of Thoracic and Cardiovascular Surgby Dr Joel D. Cooper in 1983. This achievement was
followed by the first successful double lung transplant in
1986.2
The first pediatric lung transplant (PLT) was performed at
the University of Toronto in 1987 in a 15-year-old boy with
familial pulmonary fibrosis.3 However, lung transplantation
in children has not been as widely embraced as in the adult
population. Since 1988, more than 1100 PLTs have been per-
formedworldwide, with consistent improvement in survival.
In recent years, approximately 70 to 75 PLTs have been
performed yearly in 28 centers across the world, with only
2 centers performing more than 10 transplants each year.4
Since the 1980s, survival in pediatric heart transplanta-
tion has improved significantly.5 However, the present
authors previously demonstrated that all improvements in
survival were in reality only an increase in early survival.6
After the first posttransplant year, survival in pediatric heart
transplantation has not changed in more than 2 decades. To
observe whether the same phenomenon exists in PLT, an
analysis of all the PLTs recorded in the Organ Procurement
and Transplantation Network (OPTN) Thoracic Registry
was undertaken.MATERIALS AND METHODS
A retrospective analysis of OPTN data as of May 2008 was performed.
The OPTN is the unified transplant network established by the Unitedery c March 2011
Abbreviations and Acronyms
BO ¼ bronchiolitis obliterans
OPTN ¼ Organ Procurement and Transplantation
Network
PLT ¼ pediatric lung transplant
Zafar et al Cardiothoracic TransplantationStates Congress under the National Organ Transplant Act of 1984. The
United Network for Organ Sharing is a private, nonprofit organization
that administers the OPTN under federal contract.
Analysis was limited to patients in the United Network for Organ Shar-
ing/OPTN Thoracic database who were aged less than 18 years and who
underwent lung transplantation between May of 1988 and May of 2008.
Of a total of 17,207 lung transplants, 959 (5.5%) were PLTs. Patients
were divided according to the year of transplant into 3 groups: early
(1988–1994), mid (1995–2001), and late (2002–2008) eras.
There were 490 possible data points; many of these fields were infre-
quently populated. Therefore, the analysis was limited only to the variables
that were at least 80% populated, with the exception of cytomegalovirus
mismatch for which only 40% had the information available. Twenty-
five variables met this criterion; on the average, these variables were
95% populated. For baseline characteristics, continuous variables were
compared using t test and analysis of variance, with the Tukey method
for controlling for multiple comparisons. Categoric variables were com-
pared using the chi-square test. Survival curves were estimated using the
Kaplan–Meier method, and equality of survival curves was tested using
a log-rank test. Multivariate analyses were performed using Cox propor-
tional hazards regression models.RESULTS
Demographics
The mean age and weight of the recipients were 12 5.6
years and 33.6  16.3 kg, respectively, and the mean age
and weight of the donors were 17.6  15 years and 41.6
 24 kg, respectively. A total of 106 (11%) of the total co-
hort were infants (aged1 year), 299 (31%) were aged 2 to
12 years, and 554 (58%) were adolescents (aged 13
years). A total of 546 (57%) were girls. Ethnic composition
of the cohort was Caucasian (83%, 795), Hispanic (8%,FIGURE 1. Kaplan–Meier curves: patient survival in diff
The Journal of Thoracic and Ca80), African American (5%, 50), and others (4%, 34).
Some 51% (490) of the cohort had a gender-matching
transplant. Gender-mismatch transplants consisted of
female recipients who had a male donor (29%, 273) and
male recipients who had a female donor (20%, 196).
Some 48% (264/554) of the adolescents had an adult donor.
A median of 51 (1–73) transplants were performed each
year over the 20 years, and a median of 60 (57–62) trans-
plants were performed over the last 5 years.Pretransplant Characteristics
Pretransplant diagnosis was cystic fibrosis in 505 patients
(53%), primary pulmonary hypertension in 104 patients
(11%), transplant-related bronchiolitis obliterans (BO) in
50 patients (5%), primary BO in 34 patients (3.5%), inter-
stitial lung disease in 32 patients (3%), and other diseases in
218 patients (28%). Incidences of different diagnosis are
outlined in Table E1 (available online). Some 31% of pa-
tients (298) were receiving steroids, and 16% of patients
(155) were ventilator dependant at the time of transplant;
7% of patients (64) had a pan-resistant bacterial infection
before transplant, and in the last 2 years this incidence
had significantly increased (P < .001) to 22% (17/76);
13% of patients (125) had a previous thoracic operation
that was nontransplant related. Median overall waiting
time was 5 (0–96) months. Infants (1 [0–7] months) had
a significantly shorter (P<.001) waiting time than those
aged 2 to 12 years (4 [0–84] months) and adolescents
(8 [0–96] months).Transplantation and Posttransplant Characteristics
Bilateral lung transplantation was performed in 94%
(899) of the cohort, and retransplantation was performed
in 8% (81) of the cohort. A living donor transplant was
performed in 11% (106) of PLTs, with only 2 (1.5%)
performed in last 3 years. Mean organ ischemic time was
5  2 hours.erent eras (A) and graft survival in different eras (B).
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FIGURE 2. Kaplan–Meier curves conditional on 1-year survival: patient survival in different eras (A) and Graft survival in different eras (B).
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infection requiring treatment 46% (441), bronchial stricture
3% (27), and airway dehiscence 0.8% (8). Median length
of hospital stay was 19 days (1–326 days), and this has
not changed significantly (P>.05) among the eras.Patient and Graft Survival
Kaplan–Meier survivals (both patient and graft) were sig-
nificantly better in the late era compared with the other 2
eras (P< .05) (Figure 1). Kaplan–Meier survival condi-
tional on 1 year was not significantly different (P> .2)
among the eras (Figure 2) for patient or graft. Some 51%
(490) of the cohort were reported as dead. The cause of
death was graft failure in 35% (169) and infection in
23% (114). Causes of death are outlined in Table E2 (avail-
able online). Overall graft survival is shown in Figure 3.
Table 1 shows overall graft survival and comparison of sur-
vival for different eras at 1, 3, and 5 years. Patient survival
for children aged 2 to 12 years was better than for children
aged 13 to 18 years; however, graft survival was not signif-
icantly different among age groups (Figure 4).FIGURE 3. Overall graft survival.
830 The Journal of Thoracic and Cardiovascular SurgMultivariate Analyses of Patient Survival
Gender, age groups, diagnosis, and cytomegalovirus mis-
match did not significantly affect overall patient or graft sur-
vival. Chronic steroid dependence (P ¼ .02), pretransplant
ventilator dependence (P < .001), and retransplantation
(P¼ .02) were associated with significantly increased over-
all mortality (Table 2). The risk factors for early mortality
(1 year) were the same as for overall mortality. However,
there were no risk factors found to be associated with late
mortality (>1 year).DISCUSSION
Lung transplantation has moved into a new era of success
with 3 major changes: (1) the advent of currently used sur-
gical techniques by Patterson and associates,7 addressing
the issues of airway anastomosis and prolonged ischemia;
(2) the introduction of cyclosporine in 1983, which resulted
in dramatically improved survival; and (3) the adoption of
close collaboration between the medical and surgical teams
in the care of these patients that has continued to improve
outcomes.
The results of the current analysis substantiate the infer-
ence made by the 2008 International Society for Heart &
Lung Transplantation registry that survival in the late era
of PLT is significantly greater than in the earlier eras.4 This
difference is clearly driven by an improvement in 1-year
(early) survival as highlighted by the conditional 1-year sur-
vival curves that are virtually identical for the different eras
(Figure 2). These survival curves censor 1-year mortality soTABLE 1. Graft survival
Graft survival
Overall Early era Mid era Late era
1 y 74% 62% 75% 81%
3 y 53% 43% 52% 61%
5 y 40% 36% 38% 43%
Half life 3.4 y 2.2 y 3.3 y 3.8 y
ery c March 2011
FIGURE 4. Kaplan–Meier curves: patient survival for different age groups (A) and graft survival for different age groups (B).
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sible. We reported the same phenomenon in pediatric heart
transplantation.6 This improvement in early PLT survival is
likely due to advances in surgical, anesthetic, and critical
care management, and improvements in lung preservation,
infection control, and strategies to combat early rejection.
Also, the refinement in candidate selection over the years
as the field has matured likely has helped to improve early
survival. For example, unlike in the 1990s, few centerswould
now perform transplantation in patients with cystic fibrosis
who are on ventilators. However, no significant advances
have been made to treat chronic rejection in pediatric lung
or heart transplantation since the introduction of cyclospor-
ine in 1983. BO remains the most common cause of PLT
graft failure beyond the first year of transplant.4 Enormous
amounts ofwork have been done recently to understand early
diagnosis and treatment of BO.8-10 However, despite shifting
trends in immunosuppression (ie, increased use of
mycophenolate, sirolimus, and tacrolimus), the mortality
rate for PLT after the first posttransplant year has not
changed in more than 20 years.4TABLE 2. Risk factors analyzed for graft loss
Multivariate survival analysis
95% CI
Hazard ratio Lower Upper
Gender (female) 1.058 .831 1.346
Gender-mismatch 1.118 .853 1.465
Age 1.015 .996 1.034
Diagnosis (cystic fibrosis) 1.096 .837 1.436
Pretransplant steroid dependence 1.274 1.582 1.027
Pretransplant ventilator dependence 1.789 2.304 1.387
Retransplantation 1.681 2.660 1.063
Ischemic time>6 h 1.122 1.385 0.908
Pretransplant pan-resistant bacterial
infection
1.222 1.821 0.821
CMV mismatch 1.222 1.821 0.821
CI, Confidence interval; CMV, cytomegalovirus.
The Journal of Thoracic and CaPretransplant chronic steroid use, ventilator dependence,
and retransplantation were found to be independent risk fac-
tors for poor graft survival, as has been reported by other
groups.11,12 Although mechanical ventilation is a significant
risk factor for morbidity and mortality in adults and older
children, the impact on infants is less clear.13,14 Nonetheless,
in this analysis pretransplant mechanical ventilatory support
is an independent risk factor for graft failure at all ages. In
this cohort, mid to late survival (>1 year) seemed to be
unaffected by any of the variables analyzed.
Although there is conflicting evidence regarding the
impact of pretransplant pan-resistant bacterial infection on
the outcome of lung transplant recipients,15-18 the present
study did not show it to be a risk factor for mortality.
However, a significant increase over the past few years in
the incidence of pan-resistant bacterial infection is noted at
the timeof registration,which is concerningbecause it is com-
mon to isolate identical bacteria from the lungs of patients af-
ter lung transplantation compared with those infecting the
patients preoperatively.19 Gram-negative infection in patients
with cystic fibrosis, particularly certainBurkholderia cepacia
complex infections, has been associated with poor outcomes
and early mortality posttransplant.19,20 Burkholderia
cenocepacia (previously known as Genomovar 3), a virulent
species of Burkholderia, is considered an absolute
contraindication to lung transplantation in most centers.
Although the use of multiple combinations of bactericidal
antibiotics for eradication of Burkholderia species has been
proposed, empiric evidence of successful outcome after
lung transplantation, especially in regard to B. cenocepacia,
is still lacking.T
XCONCLUSIONS
Early posttransplant survival has significantly improved
to such an extent that it has prolonged the overall survival
after PLT dramatically. Unfortunately, chronic rejection
continues to dominate late graft survival with littlerdiovascular Surgery c Volume 141, Number 3 831
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Ximprovement in affective therapies. Therefore, in patients
surviving the first posttransplant year, the subsequent mor-
tality rate has not changed in more than 2 decades. There is
an increasing need for novel therapies focused on improv-
ing the long-term survival in these patients.
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TABLE E1. Pretransplant diagnosis
Diagnosis Frequency Percent
Cystic fibrosis 505 52.7
Primary pulmonary hypertension 104 10.8
Graft rejection 81 8.4
Bronchiolitis obliterans 50 5.2
Obstructive 1 .1
Acute rejection 1 .1
Restrictive 3 .3
Nonspecific 6 .6
Primary graft failure 8 .8
Other 12 1.3
Primary bronchiolitis obliterans 34 3.5
Idiopathic pulmonary fibrosis 32 3.3
Pulmonary fibrosis other cause 18 1.9
Pulmonary vascular disease 14 1.5
Bronchiectasis 9 .9
Eisenmenger’s syndrome 17 1.7
COPD/emphysema 7 .7
Surfactant protein B deficiency 5 .5
Bronchopulmonary dysplasia 4 .4
Other 129 13.7
COPD, Chronic obstructive pulmonary disorder.
TABLE E2. Causes of death
Cause of death Frequency Percent
Graft failure 169 34.6
Primary failure 21 4.3
Rejection hyperacute 2 .4
Rejection acute 5 1.0
Rejection chronic 98 20.1
Technical 3 .6
Graft infection 12 2.5
Recurrent disease 2 .4
Nonspecific 26 5.3
Infection 114 23.3
Bacterial 48 9.8
Viral 24 4.9
Fungal 25 5.1
Mixed 5 1.0
Other 12 2.5
Cardiovascular (myocardial infarction, cardiac
arrest, ventricular failure, cardiogenic
shock)
18 3.7
Pulmonary 84 17.1
Dehiscence 3 .6
Bronchiolitis 23 4.7
Primary pulmonary hypertension 2 .4
Pulmonary embolism 2 .4
Respiratory failure 47 9.6
Acute respiratory distress 2 .4
Other 5 1.0
Cerebrovascular 15 3
Stroke 3 .6
Hemorrhage (nonstroke) 7 1.4
Brain anoxia 3 .6
Other 2 .4
Hemorrhage 11 2.2
Gastrointestinal 3 .6
Intraoperative 2 .4
Postoperative 3 .6
Respiratory 3 .6
Malignancy 14 2.8
Metastatic other specify 1 .2
Primary other specify 1 .2
Posttransplant lymphoproliferative disorder 5 1.0
Lymphoma 7 1.4
Intraoperative: not hemorrhage 1 .2
Renal failure 2 .4
Multiple organ failure 25 5.1
Noncompliance 4 .8
Unknown 33 6.8
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